Loading organizations...

Rhythm Pharmaceuticals is a technology company.
Rhythm Pharmaceuticals is a global biopharmaceutical company focused on precision medicines for rare neuroendocrine diseases. Its FDA-approved core product, IMCIVREE (setmelanotide) injection, is a melanocortin-4 receptor (MC4R) agonist. This therapy addresses severe obesity and hyperphagia from genetic impairments in the MC4R pathway, treating POMC, LEPR, Bardet-Biedl syndrome, and acquired hypothalamic obesity.
Founded in Boston in 2008 by Bart Henderson and Elizabeth Stoner, Rhythm Pharmaceuticals was conceived from the insight that specific genetic defects in the MC4R pathway cause severe obesity and intractable hunger. Henderson shaped its early strategy, and Dr. Stoner, a clinical development expert, provided the scientific foundation for their therapeutics.
It serves patients and families managing rare genetic diseases of obesity, who face substantial challenges. Rhythm envisions empowering them to live fulfilling, unburdened lives. Its mission transforms patient care by advancing precision medicines addressing these disorders' fundamental genetic causes.
Rhythm Pharmaceuticals has raised $199.0M across 6 funding rounds.
Rhythm Pharmaceuticals has raised $199.0M in total across 6 funding rounds.
Rhythm Pharmaceuticals has raised $199.0M in total across 6 funding rounds.
Rhythm Pharmaceuticals's investors include Deerfield Management, Ipsen, MPM Capital, New Enterprise Associates, OrbiMed, Third Rock Ventures, Foresite Capital, Venrock, 5AM Ventures, Pfizer Venture Investments, Red Tree Venture Capital, Marc de Garidel.
Rhythm Pharmaceuticals is a global commercial-stage biopharmaceutical company, not a technology company, specializing in rare melanocortin-4 receptor (MC4R) pathway diseases that cause hyperphagia and severe obesity.[1][2][3] It develops and commercializes precision medicines like IMCIVREE (setmelanotide), the first FDA-approved therapy for obesity due to pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), leptin receptor (LEPR) deficiencies, or Bardet-Biedl syndrome (BBS) in patients 6 years and older.[2][3] The company serves patients and families with these rare genetic neuroendocrine disorders, addressing unmet needs by targeting the root cause of uncontrollable hunger and obesity through MC4R pathway signaling restoration.[1][3] Growth momentum includes FDA approval in 2020, ongoing Phase 2/3 trials for additional indications like hypothalamic obesity, the 2023 acquisition of Xinvento, and programs like the Uncovering Rare Obesity initiative for free genetic testing.[2][3]
Rhythm Pharmaceuticals was founded in 2008 in Boston, with a focus on rare neuroendocrine diseases from the start.[2] Key early milestones include dosing the first patients with setmelanotide in 2011, publishing Phase 2 results for POMC deficiency in the *New England Journal of Medicine* (2016) and LEPR deficiency in *Nature Medicine* (2018), completing an initial public offering on Nasdaq in 2017, and launching Phase 3 trials in 2019.[2] FDA approval of IMCIVREE in 2020 marked a pivotal moment, enabling commercialization, followed by expansion into broader MC4R diseases and the 2023 Xinvento acquisition to advance hypothalamic obesity trials.[2] While specific founders are not detailed in available sources, the leadership team drives innovation in therapies for these underserved patients.[2]
Rhythm rides the trend of precision medicine in rare diseases, leveraging genetic insights and biologics to address unmet needs in endocrinology and obesity.[1][2][3] Timing aligns with advances in genomic sequencing and regulatory support for orphan drugs, enabling FDA approvals for niche indications like MC4R deficiencies.[2][3] Market forces favoring it include rising awareness of genetic obesity (beyond lifestyle factors), demand for targeted therapies amid the rare disease market's growth, and partnerships like Xinvento for pipeline expansion.[2] It influences the ecosystem by pioneering MC4R research, providing diagnostic tools, and advancing data-driven care, potentially reshaping treatment for hypothalamic and genetic obesities.[3]
Rhythm's pipeline expansions, including Phase 3 hypothalamic obesity trials, position it for label extensions and broader MC4R applications, with genetic testing accelerating patient identification.[2][3] Trends like AI-enhanced genomics and orphan drug incentives will shape its path, potentially increasing market penetration in rare diseases.[3] Its influence may evolve from niche pioneer to leader in neuroendocrine precision therapies, transforming lives as diagnostics improve—correcting the misconception of it as a "technology company" underscores its biotech focus on meaningful clinical impact.[1][2]
Rhythm Pharmaceuticals has raised $199.0M across 6 funding rounds. Most recently, it raised $41.0M Debt in February 2017.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 16, 2017 | $41.0M Debt | Deerfield Management, Ipsen, MPM Capital, New Enterprise Associates, OrbiMed, Third Rock Ventures | |
| Feb 1, 2017 | $41.0M Venture Round | Foresite Capital, New Enterprise Associates, Venrock | |
| Nov 1, 2012 | $33.0M Series B | 5AM Ventures, Pfizer Venture Investments, Red Tree Venture Capital | |
| Jun 13, 2012 | $25.0M Series B | Marc de Garidel, Vaughn Kailian, Ed Mathers, Lou Tartaglia | |
| Sep 8, 2010 | $19.0M Series A Extension | New Enterprise Associates | MPM Capital, Lou Tartaglia |
| Mar 1, 2010 | $40.0M Series A | New Enterprise Associates, Todd Foley | Foresite Capital, T1D Fund, Venrock, Deerfield Management, Ipsen, Jonathan Silverstein, Third Rock Ventures, Wellington Management |